Firstsour.Solu. Q1 FY27 Earnings Call — Analysis (NSE: FSL)
Firstsource reaffirms FY27 constant currency revenue growth guidance of 10-13% and EBIT margin band 12.25-12.75% despite absorbing 1-1.5% growth headwind from a terminated healthcare BPaaS engagement.
Result quality: stable — Steady quarter. Management sentiment: optimistic.
The take
Q1FY27 Revenue ₹2,720 Cr ( +22.9% YoY ) . New guidance — FY27 fy27 constant currency revenue… 10% to 13% . New story: AI-led differentiation scaling .
Results
Revenue ₹2,720 Cr (+22.9% YoY, +12.3% CC); EBIT margin 12.4% (+110 bps YoY); adjusted net profit ₹220 Cr.
Financial highlights
| Metric | Value | Change | Basis |
|---|---|---|---|
| Revenue | ₹2,720 Cr | +22.9% | yoy · Q1FY27 |
| Revenue (QoQ) | ₹2,720 Cr | +5.5% | qoq · Q1FY27 |
| Constant Currency Revenue Growth | 12.3% | yoy · Q1FY27 · constant currency | |
| Revenue (US$) | $288 million | +11.2% | yoy · Q1FY27 |
| EBIT | ₹337 Cr | +34.8% | yoy · Q1FY27 |
| EBIT Margin | 12.4% | +110 bps | yoy · Q1FY27 |
| Adjusted Net Profit | ₹220 Cr | +31.2% | yoy · Q1FY27 |
| Cash and Bank Balances | ₹300 Cr | point_in_time · Jun-26 · as of Jun-26 | |
| Net Debt | ₹1,710 Cr | point_in_time · Jun-26 · as of Jun-26 | |
| DSO | 67-69 days | none · Q1FY27 | |
| Headcount | 36,875 | +670 | qoq · Q1FY27 |
Guidance
Full-year FY27 constant currency revenue growth guidance reaffirmed at 10-13%, EBIT margin band 12.25-12.75%, and long-term EBIT margin target of 14-15% over the next 2-3 years.
What management committed to
- Firstsource expects constant currency revenue growth of 10% to 13% for FY27. — 10% to 13%, FY27
- Firstsource expects EBIT margin in the range of 12.25% to 12.75% for FY27. — 12.25% to 12.75%, FY27
- Firstsource targets EBIT margin of 14% to 15% over the next two to three years (by FY29-FY30). — 14% to 15%, FY29-FY30
- Effective tax rate for FY27 is expected to be between 22% and 24%. — 22% to 24%, FY27
- Firstsource expects to recover the INR271 million charge related to the [terminated healthcare BPaaS engagement] and the INR216 million charge related to [indemnification penalty from a claims processing issue] through client payments and insurance. — INR271 million and INR216 million, over the coming quarter(s)
Key themes
AI-led differentiation and large deal momentum offset healthcare headwind
How the narrative shifted
- AI-led differentiation scaling: Management positions its Kairos AI platform as a full-stack operating system that moves clients from AI experimentation to production at scale, evidenced by live deployments across top mortgage lenders, health plans, and card issuers.
- Healthcare volatility absorbed: A terminated healthcare BPaaS engagement due to client leadership change is portrayed as isolated; reaffirmed guidance demonstrates portfolio resilience and strong offsetting deal wins, reinforcing confidence in healthcare's strategic value.
- Large deal momentum and wallet deepening: Six straight quarters of 4+ large deals and highest ACV intake in 4 quarters, plus 80% growth in $5M+ clients over two years, underscore execution and share-of-wallet gains.
- Nearshore/offshore shift accelerating: Europe and South Africa delivery growth, with South Africa as fastest-growing geography, driven by nearshore demand; Glasgow regulatory office addition highlights capability expansion.
- Margin expansion trajectory intact: Seventh straight quarter of EBIT margin improvement; FY27 guidance 12.25-12.75% and long-term target 14-15% in 2-3 years signal confidence in operational efficiency and mix shift.
- Regulatory and macro tailwinds/headwinds in BFS and healthcare: US consumer debt at record highs drives collections demand; healthcare regulatory uncertainty (HR1, CMS rate adjustments) accelerates AI adoption but creates near-term pacing effects; mortgage subdued but AI cost-takeout resonates.
Operational commentary
- Six consecutive quarters of 4+ large deals; Q1 ACV intake highest in 4 quarters; strong pipeline across verticals.
- 12 new logos added, including 3 strategic logos with potential >$5M annual revenue.
- BFS vertical CC growth 14% YoY; demand strong in collections, financial crime compliance, and AI-powered operations; pipeline robust.
- Healthcare vertical CC growth 11% YoY, -2% QoQ; payer side impacted by CMS adjustments and program timing; provider side expanding AI-driven RCM with Denials AI and voice AI agents; one BPaaS engagement terminated due to client leadership change, but $5M+ relationship intact; deal wins in healthcare remain strong (~1/3 of total).
- CMT vertical CC growth 6% YoY, 9% QoQ; volatility from consumer tech transitions, but pipeline well-balanced across telecom, EdTech, media, technology clients.
- Diverse portfolio CC growth 27% YoY; utilities steady, Pastdue Credit expanding in UK with cross-sell into customer service/collections; new logo in retail.
- Europe strong with 18% CC growth YoY; South Africa fastest-growing geography; new Glasgow office for regulatory financial services work.
- Australia revenue doubled YoY.
- AI platform Kairos: AI in production at scale – 14 of top 20 US mortgage lenders, 10 of top 15 US health plans, top US/UK card issuers; new domain AI platforms across mortgage, healthcare intake, collections.
- New growth engines launched: Middle East, South Africa, Canada; capability frontiers: US Retail/CPG, marketing services, security & resiliency services.
- Partner ecosystem: joint solutions with Zendesk (vertical-specific), Cresta AI CoE; targeted startup investments for Kairos.
- Revenue concentration declining: top 5 and top 10 client share down even as top clients grow; $5M+ clients up 80% over 2 years; 145 clients >$1M run rate.
- Offshore/nearshore hiring ~80% of gross additions; headcount stable.
Analyst Q&A
Q. Impact of healthcare BPaaS termination on Q1 revenue and nature of the exceptional charge?
Ritesh Idnani explained the termination was due to a client leadership change, not delivery issues; the charge of INR271 million covers partner obligations, and they are working to recover it. He confirmed the Q1 impact was about 1-1.5% of revenue, and reiterated confidence in recovery.
Q. Does maintaining full-year guidance imply earlier top-end now midpoint, or can the pipeline fully offset the lost growth?
Ritesh Idnani stated that Q1 saw the best deal wins in four quarters, several deals are ramping quickly, and the healthy pipeline provides comfort to reinforce the original 10-13% guidance range.
Q. Is the healthcare contract termination an isolated incident or part of broader challenges in the healthcare vertical?
Ritesh Idnani called it a very isolated, one-off instance due to a leadership change; the client continues to expand its footprint with Firstsource, and healthcare deal wins remain strong at about one-third of total wins.
Research and educational content only. Not investment advice.